rewirebio.iobenchmarks
Evidence claim

Relevance of DELFI 2019 internally cross-validated cancer detection protocol to "Select a plasma ctDNA fragmentomics detection workflow"

Use case
Select a plasma ctDNA fragmentomics detection workflow
Assessed by
DELFI 2019 internally cross-validated cancer detection protocol
Relevance
Proxy evidence
Endpoint
Sensitivity (73%, 152/208) at a reported 98% specificity for plasma cfDNA fragmentomics-based cancer detection, repeated 10-fold cross-validation (10 repeats)

A repeated 10-fold cross-validation (10 repeats) on one assembled cohort is a proxy for the broader plasma ctDNA fragmentomics detection decision and for this explicitly assessed assay endpoint; it is internal cross-validation, not a separately held-out validation cohort and not prospective screening validation.

1 reviewed evaluation

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

15 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance
Citation locations
1 values
  • source id
    amp-20261007-ctdna-fragmentomics-source
    locator
    See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/
Context-only references
Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252

Original source ↗

amp-20261007-ctdna-fragmentomics-source: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/

Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252
Retrieved: 2026-10-07T12:24:27.091080+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.citation_locators

Source artifact SHA-256: 192730a334f4752575543fb6bd9d13faa84eb27e939d918363cfe633c0358322

Hash scope: Hash scope not separately documented; inspect source record

Format: curator_factual_receipt

Constraints
2 values
  • Inspect every linked evaluation's source locator and preserved conflicts before citing a result.
  • Do not combine this mapping's evaluations with any other protocol's results.
Context-only references
Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252

Original source ↗

amp-20261007-ctdna-fragmentomics-source: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/

Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252
Retrieved: 2026-10-07T12:24:27.091080+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.constraints

Source artifact SHA-256: 192730a334f4752575543fb6bd9d13faa84eb27e939d918363cfe633c0358322

Hash scope: Hash scope not separately documented; inspect source record

Format: curator_factual_receipt

Endpoint
Sensitivity (73%, 152/208) at a reported 98% specificity for plasma cfDNA fragmentomics-based cancer detection, repeated 10-fold cross-validation (10 repeats)
Context-only references
Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252

Original source ↗

amp-20261007-ctdna-fragmentomics-source: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/

Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252
Retrieved: 2026-10-07T12:24:27.091080+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.endpoint

Source artifact SHA-256: 192730a334f4752575543fb6bd9d13faa84eb27e939d918363cfe633c0358322

Hash scope: Hash scope not separately documented; inspect source record

Format: curator_factual_receipt

Claimed field
links:assessed_by:amp-20261007-ctdna-fragmentomics-protocol
Context-only references
Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252

Original source ↗

amp-20261007-ctdna-fragmentomics-source: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/

Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252
Retrieved: 2026-10-07T12:24:27.091080+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.field

Source artifact SHA-256: 192730a334f4752575543fb6bd9d13faa84eb27e939d918363cfe633c0358322

Hash scope: Hash scope not separately documented; inspect source record

Format: curator_factual_receipt

Limitations
5 values
  • 4 of 215 healthy individuals misclassified at source-labelled 98% specificity. Retain rounded printed specificity; do not recompute sensitivity.
  • Internal repeated cross-validation is not independent prospective screening validation; clinically identified cancers and healthy comparators differ from intended screening population.
  • DELFI composite features include CNAs/mtDNA, so this exact result is not pure fragmentation alone.
  • cfDNA signal is not purified ctDNA, tumour fraction limit is unreported for this endpoint.
  • Combined mutation+DELFI 115/126 (91%) is a different subset/configuration and is excluded.
Context-only references
Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252

Original source ↗

amp-20261007-ctdna-fragmentomics-source: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/

Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252
Retrieved: 2026-10-07T12:24:27.091080+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.limitations

Source artifact SHA-256: 192730a334f4752575543fb6bd9d13faa84eb27e939d918363cfe633c0358322

Hash scope: Hash scope not separately documented; inspect source record

Format: curator_factual_receipt

Pinned records
5 values
  • record id
    amp-20261007-ctdna-fragmentomics-evaluation
    fields
    • status
    • links
    • attributes.origin
    • attributes.comparison
    sha256
    a79d0eab434ea82303e0d9a5183c1189f5b2aa218bf353fc33b380fdc913c608
  • record id
    amp-20261007-ctdna-fragmentomics-protocol
    fields
    • status
    • name
    • description
    • facets
    • source_ids
    • links
    • attributes
    sha256
    2c598a384f147b78f0491c9b7f083bc9e08cca23f0b30360068152b8eaf4655e
  • record id
    amp-20261007-ctdna-fragmentomics-result
    fields
    • status
    • attributes.metric
    • attributes.metric_qualifier
    • attributes.printed_value
    • attributes.numeric_value
    sha256
    d88dadfae8f33129a005dbc31526216aa8e8aa3b7da4d261f9078985d1ac4790
  • record id
    amp-20261007-ctdna-fragmentomics-source
    fields
    • status
    • attributes.artifact_sha256
    sha256
    ce4591cb119aea1a3cd4d020dc50a2b61c919728f3bb69eb047e265b3e591716
  • record id
    use-case-plasma-ctdna-fragmentomics
    fields
    • status
    • name
    • description
    • facets
    • attributes.question
    • attributes.decision
    • attributes.inputs
    • attributes.output
    • attributes.exclusions
    • attributes.setting
    • attributes.clinical_scope
    • attributes.intended_users
    sha256
    01d27c2ce64a391055bddc6dec9d5db208df9bee3d5e679045dd3f4f04a0ca08
Context-only references
Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252

Original source ↗

amp-20261007-ctdna-fragmentomics-source: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/

Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252
Retrieved: 2026-10-07T12:24:27.091080+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.pins

Source artifact SHA-256: 192730a334f4752575543fb6bd9d13faa84eb27e939d918363cfe633c0358322

Hash scope: Hash scope not separately documented; inspect source record

Format: curator_factual_receipt

Rationale
A repeated 10-fold cross-validation (10 repeats) on one assembled cohort is a proxy for the broader plasma ctDNA fragmentomics detection decision and for this explicitly assessed assay endpoint; it is internal cross-validation, not a separately held-out validation cohort and not prospective screening validation.
Context-only references
Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252

Original source ↗

amp-20261007-ctdna-fragmentomics-source: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/

Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252
Retrieved: 2026-10-07T12:24:27.091080+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.rationale

Source artifact SHA-256: 192730a334f4752575543fb6bd9d13faa84eb27e939d918363cfe633c0358322

Hash scope: Hash scope not separately documented; inspect source record

Format: curator_factual_receipt

Reason
Add Codex-checked primary-source protocol evidence from the bounded AMP intake (rewire.it#365).
Context-only references
Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252

Original source ↗

amp-20261007-ctdna-fragmentomics-source: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/

Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252
Retrieved: 2026-10-07T12:24:27.091080+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.reason

Source artifact SHA-256: 192730a334f4752575543fb6bd9d13faa84eb27e939d918363cfe633c0358322

Hash scope: Hash scope not separately documented; inspect source record

Format: curator_factual_receipt

Relevance
proxy
Context-only references
Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252

Original source ↗

amp-20261007-ctdna-fragmentomics-source: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/

Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252
Retrieved: 2026-10-07T12:24:27.091080+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.relevance

Source artifact SHA-256: 192730a334f4752575543fb6bd9d13faa84eb27e939d918363cfe633c0358322

Hash scope: Hash scope not separately documented; inspect source record

Format: curator_factual_receipt

Revision
1
Context-only references
Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252

Original source ↗

amp-20261007-ctdna-fragmentomics-source: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/

Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252
Retrieved: 2026-10-07T12:24:27.091080+00:00

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.revision

Source artifact SHA-256: 192730a334f4752575543fb6bd9d13faa84eb27e939d918363cfe633c0358322

Hash scope: Hash scope not separately documented; inspect source record

Format: curator_factual_receipt

How to read the evidence

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

1 source record and release historyDownload this release (gzip)
Technical metadata and extraction receipts

Stable ID: use-case-mapping-amp-20261007-issue15

field
links:assessed_by:amp-20261007-ctdna-fragmentomics-protocol
value
amp-20261007-ctdna-fragmentomics-protocol
relevance
proxy
endpoint
Sensitivity (73%, 152/208) at a reported 98% specificity for plasma cfDNA fragmentomics-based cancer detection, repeated 10-fold cross-validation (10 repeats)
rationale
A repeated 10-fold cross-validation (10 repeats) on one assembled cohort is a proxy for the broader plasma ctDNA fragmentomics detection decision and for this explicitly assessed assay endpoint; it is internal cross-validation, not a separately held-out validation cohort and not prospective screening validation.
constraints
Inspect every linked evaluation's source locator and preserved conflicts before citing a result.; Do not combine this mapping's evaluations with any other protocol's results.
limitations
4 of 215 healthy individuals misclassified at source-labelled 98% specificity. Retain rounded printed specificity; do not recompute sensitivity.; Internal repeated cross-validation is not independent prospective screening validation; clinically identified cancers and healthy comparators differ from intended screening population.; DELFI composite features include CNAs/mtDNA, so this exact result is not pure fragmentation alone.; cfDNA signal is not purified ctDNA, tumour fraction limit is unreported for this endpoint.; Combined mutation+DELFI 115/126 (91%) is a different subset/configuration and is excluded.
revision
1
reason
Add Codex-checked primary-source protocol evidence from the bounded AMP intake (rewire.it#365).
citation locators
source id: amp-20261007-ctdna-fragmentomics-source; locator: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/
source locator
amp-20261007-ctdna-fragmentomics-source: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/
review
method: automated-source-review; reviewer: codex; claude-sonnet; reviewer note: Claude Sonnet AMP-integration worker, bounded transcription of Codex-checked primary values; independently reviewed by Codex (workbench/amp-supervision/primary-review.md, integration-review-corrections.md); reviewed at: 2026-10-07T13:38:59Z; note: Bounded primary-source transcription, independently Codex-checked. No new model execution, independent experimental reproduction, qualified human scientific review or clinical validation.
reviewed evaluations
amp-20261007-ctdna-fragmentomics-evaluation
pins
record id: amp-20261007-ctdna-fragmentomics-evaluation; fields: status; links; attributes.origin; attributes.comparison; sha256: a79d0eab434ea82303e0d9a5183c1189f5b2aa218bf353fc33b380fdc913c608; record id: amp-20261007-ctdna-fragmentomics-protocol; fields: status; name; description; facets; source_ids; links; attributes; sha256: 2c598a384f147b78f0491c9b7f083bc9e08cca23f0b30360068152b8eaf4655e; record id: amp-20261007-ctdna-fragmentomics-result; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: d88dadfae8f33129a005dbc31526216aa8e8aa3b7da4d261f9078985d1ac4790; record id: amp-20261007-ctdna-fragmentomics-source; fields: status; attributes.artifact_sha256; sha256: ce4591cb119aea1a3cd4d020dc50a2b61c919728f3bb69eb047e265b3e591716; record id: use-case-plasma-ctdna-fragmentomics; fields: status; name; description; facets; attributes.question; attributes.decision; attributes.inputs; attributes.output; attributes.exclusions; attributes.setting; attributes.clinical_scope; attributes.intended_users; sha256: 01d27c2ce64a391055bddc6dec9d5db208df9bee3d5e679045dd3f4f04a0ca08
Related records

Suggest a correction